Poster on Cyclosert Drug Delivery Presented at AACR Meeting
PASADENA, Calif., April 16, 2007 /PRNewswire/ -- Insert Therapeutics, Inc., a majority-owned subsidiary of Arrowhead Research Corporation announced today its novel delivery system called Cyclosert(TM) will be featured in a poster presentation at the 2007 American Association for Cancer Research (AACR) Annual Meeting. In particular, this poster includes new research findings on a promising anticancer therapy that is currently under development.
Cyclosert is the first nanoparticle drug transport platform to be designed de novo and synthesized specifically to overcome limitations in existing technologies used for the systemic transport of therapeutics to targeted sites within the body. Based on small cyclic repeating molecules of glucose called cyclodextrins, Cyclosert promotes the ability of cytotoxic drugs to inhibit the growth of human cancer cells while remaining non-toxic and non-immunogenic at therapeutic doses. In particular, the system is designed to keep the drugs non-toxic until they actually reach the targeted tumor cells where the active drug is released in a controlled fashion.
The investigational drug discussed in the research, which Insert Therapeutics is developing in collaboration with German-based R&D Biopharmaceuticals, uses the Cyclosert system to deliver a potent anticancer agent called tubulysin A. Tubulysin A is a naturally occurring substance produced by myxobacteria. It is highly active against many types of cancer cells, targeting the cellular structures called microtubules, which play a crucial role in cell division. Used by itself, tubulysin A is an effective antitumor agent, but it is also highly toxic. By combining it with the Cyclosert transport system, researchers are aiming to make it non-toxic while preserving its antitumor activity.
In vitro studies showed the tubulysin-Cyclosert conjugate to be effective against multiple human cancer cell lines. The conjugate was found to be stable and 100 times more water soluble than the free drug. As the study's Lead Researcher, Thomas Schluep, Sc.D., Chief Scientific Officer at Insert Therapeutics emphasized, "Water solubility is essential for efficient delivery of drugs through the bloodstream. Tubulysin A is already better than many comparable agents in this respect, but in conjugation with Cyclosert, solubility improves dramatically."
In trials on animals, the tubulysin-Cyclosert conjugate was well tolerated, in contrast to tubulysin A alone, which was highly toxic and caused 50% mortality. The conjugate was also compared to vinblastine, an agent with a similar mechanism of action to tubulysin A. Vinblastine was found to be significantly less effective as an antitumor agent.
Testing and development is ongoing for the drug.
About Insert Therapeutics Inc.
Insert Therapeutics, Inc. (www.insertt.com), a majority-owned subsidiary of Arrowhead Research Corporation , is using its proprietary, nano-engineered, polymeric delivery system, Cyclosert(TM), to design, develop and commercialize drug-delivery-enhanced small-molecule therapeutics and nucleic acids. Cyclosert uses cyclodextrins as building blocks to create an entirely new class of biocompatible materials -- linear cyclodextrin-containing polymers that are non-toxic and non-immunogenic at therapeutic doses. Insert's affiliate company, Calando Pharmaceuticals, is using a related system for the systemic delivery of siRNA. The companies are pursuing this goal through internal research and development, and also through collaborations and partnerships with pharmaceutical and biotechnology companies.
About Arrowhead Research Corporation
Arrowhead Research Corporation (www.arrowheadresearch.com) is a leading nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our latest Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K, our Registration Statements on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
CONTACT: Robert Marshall of Insert Therapeutics, Inc., +1-925-570-3425, email@example.com
Web site: http://www.insertt.com/
Ticker Symbol: (NASDAQ-NMS:ARWR)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: April 2007